|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/19/11 Accentia Biopharmaceuticals Inc 10-K 9/30/11 53:7M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.37M
2: EX-10.57 Royalty Termination Agreement HTML 26K
3: EX-10.58 Class 4 Plan Promissory Note HTML 33K
4: EX-10.59 Stock Pledge Agreement HTML 68K
5: EX-10.60 Asset Purchase Agreement HTML 314K
6: EX-10.61 Agreement HTML 30K
7: EX-10.62 Loan Security Termination Agreement HTML 37K
8: EX-10.63 Loan Prepayment, Modification and Security HTML 40K
Termination Agreement
9: EX-10.64 Amended and Restated Secured Term Note HTML 58K
10: EX-10.65 Amended and Restated Secured Term Note HTML 58K
11: EX-10.66 Amended and Restated Secured Term Note HTML 58K
12: EX-10.67 Amended and Restated Secured Term Note HTML 58K
13: EX-21 Subsidiaries of Accentia HTML 14K
14: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
15: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
16: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
17: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
36: R1 Document And Entity Information HTML 45K
29: R2 Consolidated Balance Sheets HTML 182K
34: R3 Consolidated Balance Sheets (Parenthetical) HTML 49K
38: R4 Consolidated Statements Of Operations HTML 129K
49: R5 Consolidated Statements Of Stockholders' Deficit HTML 123K
30: R6 Consolidated Statements Of Cash Flows HTML 216K
33: R7 Company Overview And Summary Of Significant HTML 84K
Accounting Policies
27: R8 Liquidity And Management's Plans HTML 103K
25: R9 Discontinued Operations HTML 52K
50: R10 Inventories HTML 25K
40: R11 Unbilled Receivables And Unearned Revenues HTML 32K
39: R12 Intangible Assets HTML 39K
44: R13 Furniture, Equipment And Leasehold Improvements HTML 31K
45: R14 Reserve For Unresolved Claims HTML 18K
43: R15 Note Payable HTML 18K
46: R16 Convertible Long-Term Debt HTML 98K
35: R17 Other Long-Term Debt HTML 73K
37: R18 Derivative Liabilities HTML 65K
42: R19 Related Party Transactions HTML 51K
53: R20 Liabilities Subject To Compromise HTML 35K
47: R21 Income Taxes HTML 55K
31: R22 Stockholders' Equity HTML 98K
41: R23 Employee Benefit Plan HTML 21K
32: R24 Commitments And Contingencies HTML 59K
24: R25 Variable Interest Entities HTML 27K
48: R26 Pro Forma Results HTML 21K
51: R27 Subsequent Events HTML 32K
52: XML IDEA XML File -- Filing Summary XML 56K
26: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 698K
18: EX-101.INS XBRL Instance -- abpi-20110930 XML 868K
20: EX-101.CAL XBRL Calculations -- abpi-20110930_cal XML 158K
21: EX-101.DEF XBRL Definitions -- abpi-20110930_def XML 62K
22: EX-101.LAB XBRL Labels -- abpi-20110930_lab XML 582K
23: EX-101.PRE XBRL Presentations -- abpi-20110930_pre XML 353K
19: EX-101.SCH XBRL Schema -- abpi-20110930 XSD 77K
28: ZIP XBRL Zipped Folder -- 0001193125-11-345824-xbrl Zip 107K
| Certification |
Exhibit 32.2
CERTIFICATIONS
In connection with the Annual Report on Form 10-K of Accentia Biopharmaceuticals, Inc. (the “Company”) for the year ended September 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Form 10-K”), I, Garrison J. Hasara, Acting Chief Financial Officer and Controller of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Form 10-K fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: December 19, 2011
| Garrison J. Hasara, CPA |
| Acting Chief Financial Officer; Controller |
This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission, and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Annual Report on Form 10-K), irrespective of any general incorporation language contained in such filing.
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 12/19/11 | None on these Dates | ||
| For Period end: | 9/30/11 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/14/12 SEC UPLOAD¶ 10/20/17 1:47K Accentia Biopharmaceuticals Inc. 3/07/12 SEC UPLOAD¶ 10/20/17 1:58K Accentia Biopharmaceuticals Inc. |